AIM ImmunoTech reports Ampligen pancreatic cancer data: OS improvement 7.2 months vs historical controls

AIM ImmunoTech Inc.

Named Patient Program shows PFS 12.6 months (+4 mo) and OS 19.7 months (+7.2 mo) vs historical controls.
DURIPANC Phase 2 with AstraZeneca's Imfinzi interim data suggests improved QoL; mid-2026 report due June.
Stratified by Neutrophil/Lymphocyte ratio <4.5: PFS 17.7 months (+9.1 mo) and OS 34.8 months (+22.3 mo).
CA 19-9 <1000 subgroup: PFS 13.1 months (+4.5 mo) and OS 24.1 months (+11.6 mo).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.